Endocrine Abstracts

Context: Possible increased risk of malignancy in patients treated with denosumab has been concerned due to inhibition of the immune modulator receptor activator of nuclear factor κ-B ligand.Objective: To assess the risk of malignancy associated with denosumab treatment.Data Sources: PubMed and Cochrane Central Register of Controlled Trials were searched up to May 27, 2019.Study Selection: All randomized...